[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580966":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":32,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":10},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8,12,17,20],{"label":9,"type":10,"description":11,"interventionNames":10},"early COPD with placebo",null,"1. Age \\\u003C50 years of age with at least 10 pack-years of smoking history and one of the following: FEV1\u002FFVC\\< 0.7, abnormal computer tomography (CT) and a decline in FEV1 of at least 60mL\u002F year.\n2. Treatment with Placebo",{"label":13,"type":10,"description":14,"interventionNames":15},"early COPD with triple inhalation therapy","1. Age \\\u003C50 years of age with at least 10 pack-years of smoking history and one of the following: FEV1\u002FFVC\\< 0.7, abnormal computer tomography (CT) and a decline in FEV1 of at least 60mL\u002F year.\n2. Treatment with triple inhalation therapy",[16],"Drug: Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol",{"label":18,"type":10,"description":19,"interventionNames":10},"pre-COPD with placebo","1. It involved individuals of any age who had respiratory symptoms with or without structural (imaging-suggested emphysema) and\u002For functional abnormalities, without airflow limitation (FEV1\u002FFVC≥0.70), and who may develop persistent airflow limitation over time.\n2. Treatment with Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"pre-COPD with triple inhalation therapy","1. It involved individuals of any age who had respiratory symptoms with or without structural (imaging-suggested emphysema) and\u002For functional abnormalities, without airflow limitation (FEV1\u002FFVC≥0.70), and who may develop persistent airflow limitation over time.\n2. Treatment with triple inhalation therapy",[16],[25],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol","The intervention group was given budigfovir once a day, the dose was 160ug\u002F7.2ug\u002F4.8ug by inhalation",[13,21],[31],"placebo",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","yanmengkang","professor","100580966","early-screening-of-young-copd-and-pre-copd-100580966",false,"NCT06844175","Early Screening of Young COPD and Pre-COPD","A Prospective, Multicenter Cohort Study of Multidimensional Screening and Triple Drug Intervention in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1\\. Age 20-70 years old; 2. smoking history ≥10 pack-years or presence of visually visible emphysema on low-dose CT scan; 3. Able to tolerate or cooperate with pulmonary function test; ④4.able to understand the study and sign the relevant informed consent.\n\nExclusion Criteria:\n\n1.History of acute or chronic respiratory diseases other than COPD, including interstitial lung disease, bronchiectasis, pulmonary infection, tumor, or lung surgery; 2.patients previously diagnosed with clinical COPD; 3.Severe liver and kidney dysfunction; 4.serious heart failure or malignant arrhythmia; 5.acute cerebrovascular events within the past 3 months; 6.malignant tumor without cure; 7.the history of mental illness; 8.breastfeeding, pregnancy or planned pregnancy; 9.Subjects who are expected to be unable to cooperate and follow up.","ALL","20 Years","70 Years",{"count":47,"type":48},100,"ESTIMATED","OBSERVATIONAL","At present, patients with early COPD and pre-COPD have not been paid attention to in clinical work. This study aims to actively screen such patients in high-risk groups to clarify their prevalence, monitor and analyze relevant clinical and biological indicators, and find sensitive indicators to assist in early diagnosis. Based on the updated definition of COPD in GOLD2022, we pay attention to the concept of early COPD and pre-COPD. After the completion of patient enrollment and data collection, we will further explore the effect of triple inhaled drug intervention on the development of lung function in patients with early COPD and pre-COPD, so as to provide clinical support for early screening and early treatment of COPD.\n\n1. Patients with early COPD and pre-COPD were selected from 20 hospitals in 17 cities of Shandong province to understand the prevalence and basic characteristics of such diseases in the province, and then were divided into groups and treated.\n2. The specificity and sensitivity of pulmonary function parameters (FEV1%,FEV1\u002FFVC, DLco, etc.) and imaging parameters (MLD, Perc15, %LAA-950HU, etc.) alone or in combination in the diagnosis of early COPD and pre-COPD, and the predictive diagnostic model\u002Fsystem was established.\n3. Treatment of early COPD and pre-COPD: eligible patients were given triple inhalation therapy or placebo, and the effects of triple inhalation therapy or not on clinical symptoms, pulmonary function, and imaging parameters were compared.\n\nThis study aims to determine the prevalence of early COPD in Shandong province and provide a reference for the treatment of this population.",[52],"Pulmonary Disease, Chronic Obstructive","NOT_YET_RECRUITING","2025-02-19",{"date":56,"type":57},"2025-02-25","ACTUAL",{"date":59,"type":48},"2025-03-01",{"date":61,"type":48},"2026-12-30",{"name":34,"class":6}]